Publication
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerColorectal Adenocarcinomacivic_curation1.00
- drugEntrectinibcivic_curation1.00
- geneNTRK1civic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
- variantNTRK1 G595Rcivic_curation1.00
- variantNTRK1 G667Ccivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26546295
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NTRK1 Fusion1 | ||||||||
| Entrectinib | Colorectal Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID2960A gene fusion between exon 11 of LMNA and exon 10 of NTRK1 was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, and third-li… (full text at CIViC) PMID 26546295 · Russo et al., 2016 · Open in CIViC | civic |
| NTRK1 Fusion + NTRK1 G595R + NTRK1 G667C1 | ||||||||
| Entrectinib | Colorectal Adenocarcinoma | Predictive | C | Supports Resistance | 4 | accepted | EID2961A gene fusion between exon 10 of NTRK1 and exon 11 of the LMNA genes was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, an… (full text at CIViC) PMID 26546295 · Russo et al., 2016 · Open in CIViC | civic |